You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 295 No. 5, February 1, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (35)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Transplantation
 •Bone Marrow Transplantation
 •Immunology
 •Immunologic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Bone Marrow Transplantation for Severe Combined Immune Deficiency

Eyal Grunebaum, MD; Evelina Mazzolari, MD; Fulvio Porta, MD; Daniela Dallera, RN; Adelle Atkinson, MD, FRCPC; Brenda Reid, RN, MN; Luigi D. Notarangelo, MD; Chaim M. Roifman, MD, FRCPC

JAMA. 2006;295:508-518.

Context  Bone marrow transplantation (BMT) using stem cells obtained from a family-related, HLA-identical donor (RID) is the optimal treatment for patients with severe combined immune deficiency (SCID). In the absence of an RID, HLA-mismatched related donors (MMRDs) are often used. However, compared with RIDs, use of MMRDs for BMT is associated with reduced survival and inferior long-term immune reconstitution. Use of HLA-matched unrelated donors (MUDs) represents another potential alternative for BMT.

Objective  To compare outcomes and immune reconstitution in a large cohort of patients with SCID who received RID, MUD, or MMRD BMT.

Design, Setting, and Patients  Retrospective study of medical records from 94 infants diagnosed as having SCID who received BMT between 1990 and 2004 at 1 Canadian and 1 Italian pediatric referral center. Thirteen, 41, and 40 patients received RID, MUD, and MMRD BMT, respectively.

Main Outcome Measures  Survival and graft failure, along with incidence of graft-vs-host disease, infections, and other complications; immune reconstitution was assessed in children who survived for more than 2 years after BMT.

Results  Survival after RID BMT was highest. Twelve (92.3%) of 13 patients who received RID BMT, 33 (80.5%) of 41 who received MUD BMT, and 21 (52.5%) of 40 patients who received MMRD BMT survived. Compared with MMRD BMT, survival was significantly higher with RID (P = .008) or with MUD (P = .03). Graft failures and need for repeat BMT were more common in patients receiving MMRD BMT than in those who underwent MUD BMT. Long-term reconstitution of a full T-cell repertoire was achieved more frequently following MUD BMT (94.7%) than after MMRD BMT (61.1%) (P = .02). Acute graft-vs-host disease was documented in 73.1% of patients following MUD BMT but in only 45% after MMRD BMT (P = .009). Conversely, interstitial pneumonitis was observed more frequently after MMRD BMT (14 [35.0%] of 40) than after MUD BMT (3 [7.3%] of 41; P = .002).

Conclusion  Our study suggests that in the absence of a relative with identical HLA, MUD BMT may provide better engraftment, immune reconstitution, and survival for patients with SCID than MMRD BMT.


Author Affiliations: Division of Immunology/Allergy, Department of Paediatrics (Drs Grunebaum, Atkinson, and Roifman and Ms Reid), and Infection, Immunity, Injury and Repair Program, Research Institute (Drs Grunebaum and Roifman), Hospital for Sick Children and University of Toronto, Toronto, Ontario; and Department of Pediatrics and Angelo Nocivelli Institute for Molecular Medicine (Drs Mazzolari, Porta, and Notarangelo), and Pediatric Bone Marrow Transplantation Unit, Department of Pediatrics (Ms Dallera), University of Brescia Spedali Civili, Brescia, Italy.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How I treat ADA deficiency
Gaspar et al.
Blood 2009;114:3524-3532.
ABSTRACT | FULL TEXT  

ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency
Sauer et al.
Blood 2009;114:3216-3226.
ABSTRACT | FULL TEXT  

Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency
Neven et al.
Blood 2009;113:4114-4124.
ABSTRACT | FULL TEXT  

Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti et al.
NEJM 2009;360:447-458.
ABSTRACT | FULL TEXT  

Stem cell transplantation
Fung et al.
ASH-SAP 2007;2007:328-360.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.